Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006799 · ClinicalTrials.gov registry record · Phase 3
Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT00006799 is a Phase 3 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 13 participants.
The verdict
NCT00006799, a Phase 3 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss caused by cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting weight loss and improving quality of life in patients who have head and neck cancer and are undergoing radiation therapy.
Interventions
- PROCEDURE quality-of-life assessment
- DRUG megestrol acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2000-10-01 |
| Est. Completion | 2002-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006799
The ClinicalTrials.gov registry entry for NCT00006799 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00006799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006799 about?
NCT00006799 is a clinical study titled "Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer". RATIONALE: Megestrol helps improve appetite. It is not yet known if megestrol is effective in limiting weight loss caused by cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of megestrol in limiting weight loss and improving quality of life in patients who have head and ne...
What is the current status of trial NCT00006799?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2000-10-01. Estimated completion is 2002-09-06.
What interventions are being tested in trial NCT00006799?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00006799?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.